Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01668654 · ClinicalTrials.gov registry record · Phase 3
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT01668654 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 4 participants.
The verdict
NCT01668654, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of retigabine/ezogabine as an adjunctive treatment in subjects with either partial onset seizures (12 to \< 18 years old) or Lennox-Gastaut Syndrome (12 to \<30 years old) who have participated in a previous ("parent") study.
Interventions
- DRUG retigabine/ezogabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-09-04 |
| Est. Completion | 2013-06-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01668654
The ClinicalTrials.gov registry entry for NCT01668654 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which retigabine/ezogabine is the first listed.
NCT01668654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01668654 about?
NCT01668654 is a clinical study titled "Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS". The purpose of this study is to evaluate the long-term safety and tolerability of retigabine/ezogabine as an adjunctive treatment in subjects with either partial onset seizures (12 to \< 18 years old) or Lennox-Gastaut Syndrome (12 to \<30 years old) who have participated in a previous ("parent") st...
What is the current status of trial NCT01668654?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2012-09-04. Estimated completion is 2013-06-18.
What interventions are being tested in trial NCT01668654?
The interventions under investigation include: retigabine/ezogabine (DRUG).
Who is sponsoring clinical trial NCT01668654?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.